Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Hold Rating at Jefferies Financial Group

Jefferies Financial Group restated their hold rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report released on Monday morning, Marketbeat.com reports. They currently have a $330.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $522.00.

A number of other research firms also recently issued reports on ALNY. Needham & Company LLC cut their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price for the company. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Finally, Wells Fargo & Company reduced their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $468.84.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $318.91 on Monday. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The business has a 50 day moving average price of $342.78 and a 200-day moving average price of $408.50. The company has a market cap of $42.29 billion, a PE ratio of 186.50 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the firm earned ($0.65) EPS. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. Equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,775 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the sale, the executive vice president owned 23,406 shares in the company, valued at approximately $7,483,834.44. This trade represents a 7.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the sale, the chief executive officer directly owned 98,628 shares in the company, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 53,923 shares of company stock worth $18,072,087. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $25,000. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth $27,000. HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $27,000. Finally, Golden State Wealth Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.